Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split aims to regain compliance with Nasdaq listing requirements.
The Company's common stock is expected to begin trading on a split-adjusted basis on August 18, 2025.
Reverse Stock Split
Company effecting a 1 for 3 reverse stock split to increase share value.
Compliance Strategy
Plan to regain compliance with Nasdaq listing rule 5550(a)(2) requiring a minimum bid price of $1.00 per share.
Impact on Shares
Outstanding common stock to be reduced from 4.77 million shares to approximately 1.59 million shares.
- The reverse stock split is a strategic move to enhance shareholder value and market perception.
- Reducing the outstanding shares can lead to a potential increase in share price post-split.
The reverse stock split signals Entero Therapeutics' commitment to maintaining its Nasdaq listing and shareholder value.